COMMUNIQUÉS West-GlobeNewswire
-
Step Pharma announces completion of €38 million Series C financing
15/10/2025 -
Daxor’s New BVA Technology To Be Showcased At MedAxiom CV Transforum Fall '25
15/10/2025 -
Amarin to Report Third Quarter 2025 Financial Results and Host Conference Call on October 29, 2025
15/10/2025 -
Rezolute to Participate in Upcoming Investor Conferences
15/10/2025 -
Regeneron Showcases Advances Across Oncology Portfolio and Pipeline at ESMO, Highlighting Novel and Patient-Focused Approach for Difficult-to-Treat Cancers
15/10/2025 -
Fortrea Announces Date for Third Quarter 2025 Financial Results and Conference Call
15/10/2025 -
Verano Announces Grand Opening of Zen Leaf Antwerp in 19th Century Historic Ohio Train Depot, Offering Cannabis Consumers One of the Most Unique Dispensary Shopping Experiences in the U.S.
15/10/2025 -
Bexorg Raises $42.5M to Transform CNS Drug Development with World’s First Integrated AI and Whole-Human Brain Platform
15/10/2025 -
Algernon Pharmaceuticals Completes Name Change to Algernon Health
15/10/2025 -
Gyre Therapeutics Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Pirfenidone Capsules for the Treatment of Pneumoconiosis
15/10/2025 -
Transpire Bio Granted Orphan Drug Designation by the U.S. FDA For Two Rare Diseases
15/10/2025 -
Axogen, Inc. to Report 2025 Third Quarter Financial Results on October 29, 2025
15/10/2025 -
Amphista Therapeutics nominates AMX-883, an orally available Targeted Glue™ degrader of BRD9, as its first clinical development candidate for the treatment of acute myeloid leukaemia
15/10/2025 -
Keros Therapeutics Announces Plan for Return of $375 Million in Excess Capital
15/10/2025 -
Biodesix Announces Presentations and Events at the CHEST 2025 Annual Meeting
15/10/2025 -
Communiqué de presse : Sanofi fait de Montpellier le coeur mondial de la recherche translationnelle sur les maladies auto-immunes
15/10/2025 -
MIMEDX to Host Third Quarter 2025 Operating and Financial Results Conference Call on October 29
15/10/2025 -
SCYNEXIS and GSK Resolve Their Disagreement Related to the Restart of the Phase 3 MARIO Study
15/10/2025 -
Monopar Announces Abstract Accepted for Oral Presentation at AASLD - The Liver Meeting® 2025
15/10/2025
Pages